We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+7.99%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$6.86B
AUM Growth
-$650M
Cap. Flow
-$889M
Cap. Flow %
-12.96%
Top 10 Hldgs %
69.62%
Holding
42
New
1
Increased
10
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$107M
2
PCVX icon
Vaxcyte
PCVX
+$54.1M
3
KRYS icon
Krystal Biotech
KRYS
+$36.5M
4
KYMR icon
Kymera Therapeutics
KYMR
+$27M
5
DYN icon
Dyne Therapeutics
DYN
+$21.3M

Top Sells

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$308M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$281M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$211M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$97.2M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$70.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$25.9B
$1.02B 14.94%
2,858,888
– –
ASND icon
2
Ascendis Pharma A/S
ASND
$16.6B
$745M 10.86%
4,988,888
+792,227
+19% +$107M
ARGX icon
3
argenx
ARGX
$54.9B
$671M 9.79%
1,238,467
– –
KRYS icon
4
Krystal Biotech
KRYS
$10.6B
$477M 6.96%
2,622,222
+189,222
+8% +$36.5M
MDGL icon
5
Madrigal Pharmaceuticals
MDGL
$12.4B
$431M 6.28%
2,029,000
-26,555
-1% -$6.79M
APLS
6
DELISTED
Apellis Pharmaceuticals
APLS
$320M 4.67%
11,111,111
– –
SRPT icon
7
Sarepta Therapeutics
SRPT
$1.64B
$319M 4.65%
2,555,555
-444,445
-15% -$61.4M
RNAM
8
DELISTED
Avidity Biosciences
RNAM
$316M 4.6%
6,875,000
+370,000
+6% +$16.1M
FOLD
9
DELISTED
Amicus Therapeutics
FOLD
$248M 3.61%
23,175,000
-4,225,000
-15% -$46M
ITCI
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$223M 3.25%
3,050,000
+50,000
+2% +$3.76M
XENE icon
11
Xenon Pharmaceuticals
XENE
$6.15B
$223M 3.25%
5,666,666
– –
KYMR icon
12
Kymera Therapeutics
KYMR
$8.6B
$213M 3.11%
4,500,000
+611,112
+16% +$27M
VERA icon
13
Vera Therapeutics
VERA
$2.31B
$190M 2.78%
4,309,590
– –
ARWR icon
14
Arrowhead Research
ARWR
$11.9B
$172M 2.51%
8,888,888
– –
BMRN icon
15
BioMarin Pharmaceuticals
BMRN
$11.9B
$143M 2.09%
2,038,015
-2,519,401
-55% -$211M
MLTX icon
16
MoonLake Immunotherapeutics
MLTX
$1.58B
$140M 2.04%
2,770,100
+100
+0% +$4.69K
PCVX icon
17
Vaxcyte
PCVX
$7.61B
$134M 1.96%
1,175,000
+600,000
+104% +$54.1M
SLNO
18
DELISTED
Soleno Therapeutics
SLNO
$110M 1.61%
2,181,000
+89,334
+4% +$4.28M
BCRX icon
19
BioCryst Pharmaceuticals
BCRX
$2.43B
$90.2M 1.31%
11,865,000
-705,000
-6% -$5.36M
SNDX icon
20
Syndax Pharmaceuticals
SNDX
$1.68B
$74.9M 1.09%
3,888,437
– –
OCUL icon
21
Ocular Therapeutix
OCUL
$1.84B
$70.1M 1.02%
8,060,000
– –
KURA icon
22
Kura Oncology
KURA
$785M
$69.2M 1.01%
3,541,505
– –
MRUS
23
DELISTED
Merus
MRUS
$67.7M 0.99%
1,355,000
– –
TRML
24
DELISTED
Tourmaline Bio
TRML
$57.1M 0.83%
2,222,222
– –
MNKD icon
25
MannKind Corp
MNKD
$1.2B
$55M 0.8%
8,750,000
-9,524
-0.1% -$54.7K
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Avoro Capital Advisors held 42 positions worth $6.86B, down 8.7% from $7.51B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Avoro Capital Advisors withdrew a net $889M in Q3 2024, closing 6 positions and reducing 8 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $308M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier.

Against the trend, Avoro Capital Advisors added an estimated $107M to Ascendis Pharma A/S.

  • Avoro Capital Advisors added most to Ascendis Pharma A/S in Q3 2024, an estimated $107M increase.
  • Avoro Capital Advisors's biggest Q3 2024 reduction was BioMarin Pharmaceuticals, cutting an estimated $211M.
  • Avoro Capital Advisors fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $308M.
  • Avoro Capital Advisors's ten largest holdings make up 70% of its $6.86B portfolio in Q3 2024.
  • Avoro Capital Advisors opened 1 new position and closed 6 in Q3 2024.
  • Avoro Capital Advisors's portfolio value fell 8.7% quarter-over-quarter to $6.86B.

Based on Avoro Capital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.